In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides
10.1007/978-3-642-58785-6_3
Crossref book-chapter
Springer Berlin Heidelberg
Handbook of Experimental Pharmacology (297)
Bibliography

Crooke, R. M. (1998). In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides. Antisense Research and Application, 103–140.

Authors 1
  1. R. M. Crooke (first)
References 133 Referenced 6
  1. Aguilar L, Hemar A, Dautry-Varsat A, Blumenfeld M (1996) Hairpin, dumbbell, and single-stranded phosphodiester oligonucleotides exhibit identical uptake in T lymphocyte cell lines. Antisense Nucleic Acid Drug Dey 6:157–163 (10.1089/oli.1.1996.6.157) / Antisense Nucleic Acid Drug Dey by L Aguilar (1996)
  2. Akhtar S, Juliano RL (1992) Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol 2:139–144 (10.1016/0962-8924(92)90100-2) / Trends Cell Biol by S Akhtar (1992)
  3. Akhtar S, Basu S, Wickstrom E, Juliano RL (1991) Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res 19:555–5559 (10.1093/nar/19.20.5551) / Nucleic Acids Res by S Akhtar (1991)
  4. Akhtar S, Shoji Y, Juliano RL (1992) Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA. Raven, New York, pp 133–145 / Gene regulation: biology of antisense RNA and DNA by S Akhtar (1992)
  5. Akhtar S, Beck GF, Hawley P, Irwin WJ, Gibson I (1996) The influence of polarized epithelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides. Antisense Res Dev 6:19–206 / Antisense Res Dev by S Akhtar (1996)
  6. Albrecht T, Schwab R, Peschel C, Engels HJ, Fischer T, Huber C, Aulitzky WE (1996) Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression. Ann Hematol 72:73–79 (10.1007/BF00641311) / Ann Hematol by T Albrecht (1996)
  7. Anderson RGW (1993) Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 90:10909–10913 (10.1073/pnas.90.23.10909) / Proc Natl Acad Sci USA by RGW Anderson (1993)
  8. Asseline U, Toulme F, Thoung NT, Delarue M, Montenay-Garestier T, Helen C (1984) Oligodeoxynucleotides covalently linked to intercalating dyes as base sequence-specific ligands. Influence of dye attachment. EMBO J 3:795–800 (10.1002/j.1460-2075.1984.tb01887.x) / EMBO J by U Asseline (1984)
  9. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM (1995) Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814–23 (10.1172/JCI117860) / J Clin Invest by C Beltinger (1995)
  10. Benet LA, Sheiner LB (1985) Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7th edn. Macmillan, New York, pp 3–13 / The pharmacological basis of therapeutics by LA Benet (1985)
  11. Bennett RM (1993) As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. Antisense Res Dev 3:235–241 (10.1089/ard.1993.3.235) / Antisense Res Dev by RM Bennett (1993)
  12. Bennett CF (1995) Intracellular delivery of oligonucleotides with cationic liposomes. In: Akhtar S (ed) Delivery strategies for antisense oligonucleotide therapeutics. CRC Press, Boca Raton, pp 223–232 / Delivery strategies for antisense oligonucleotide therapeutics by CF Bennett (1995)
  13. Bennett CF, Chiang M-Y, Chan H, Shoemaker JE, Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023–1033 (10.1016/S0026-895X(25)09229-6) / Mol Pharmacol by CF Bennett (1992)
  14. Bergan R, Connell Y, Fahmy B, Neckers L (1993) Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res 21:3567–3573 (10.1093/nar/21.15.3567) / Nucleic Acids Res by R Bergan (1993)
  15. Birg F, Praseuth D, Zerial A, Thuong NT, Asseline U, LeDoan T, Helene C (1990) Inhibition of simian virus 40 DNA replication in CV-1 cells by an oligodeoxynucleotide covalently linked to an intercalating agent. Nucleic Acids Res 18:2901–2908 (10.1093/nar/18.10.2901) / Nucleic Acids Res by F Birg (1990)
  16. Bishop WP, Lin J, Stein CA, Krieg AM (1995) Interruption of a transforming growth factor a autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. Gastroenterology 109:1882–1889 (10.1016/0016-5085(95)90755-6) / Gastroenterology by WP Bishop (1995)
  17. Bishop JS, Guy-Caffey JK, Ojwang JO, Smith SR, Hogan ME, Cossum PA, Rando RF, Chaudhary N (1996) Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem 271:5698–5703 (10.1074/jbc.271.10.5698) / J Biol Chem by JS Bishop (1996)
  18. Bradley MO, Chrisey LA, Hawkins JW (1992) Antisense therapeutics. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA. Raven, New York, p 285 / Gene regulation: biology of antisense RNA and DNA by MO Bradley (1992)
  19. Brown DA, Kang S-H, Gryzanov SM, De Dionisio L, Heidenreich L, Sullivan S, Xu X, Nerenberg MI (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 269:26801–26805 (10.1016/S0021-9258(18)47090-1) / J Biol Chem by DA Brown (1994)
  20. Budker VG, Knorre DG, Vlassov VV (1992) Cell membranes as barriers for antisense constructions. Antisense Res Dev 2:177–184 (10.1089/ard.1992.2.177) / Antisense Res Dev by VG Budker (1992)
  21. Butler M, Stecker K, Bennett CF (1997) Distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379–388 / Lab Invest by M Butler (1997)
  22. Campbell JM, Bacon TA, Wickstrom E (1990) Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 20:259–267 (10.1016/0165-022X(90)90084-P) / J Biochem Biophys Methods by JM Campbell (1990)
  23. Capaccioli S, Di Pasquale G, Mini E, Mazzei T Quattrone A (1993) Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and human serum. Biochem Biophys Res Commun 197:818–825 (10.1006/bbrc.1993.2552) / Biochem Biophys Res Commun by S Capaccioli (1993)
  24. Chaix C, Toulme J-J, Morvan F, Rayner B, Imbach J-L (1993) a-Oligonucleotides: an entry to a challenging class of antisense molecules. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 223–234 / Antisense research and applications by C Chaix (1993)
  25. Chavany C, Saison-Behmoaras T, LeDoan T, Puisieux F, Couvreur P, Helene C (1994) Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 11:1370–1378 (10.1023/A:1018923301967) / Pharm Res by C Chavany (1994)
  26. Chin DJ, Green GA, Zon G, Szoka FC Jr, Straubinger RM (1990) Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol 2:1091–1100 / New Biol by DJ Chin (1990)
  27. Chow TY-K, Juby C, Brousseau R (1994) Specific targeting of antisense oligonucleotides to neutrophils. Antisense Res Dev 4:81–86 (10.1089/ard.1994.4.81) / Antisense Res Dev by TY-K Chow (1994)
  28. Clusel C, Ugarte E, Enjolras NO, Vasseur M, Blumenfeld M (1993) Ex vivo regulation of specific gene expression by nanomolar concentrations of double-stranded dumbbell oligonucleotides. Nucleic Acids Res 21:3405–3411 (10.1093/nar/21.15.3405) / Nucleic Acids Res by C Clusel (1993)
  29. Cohen JS (1993) Phosphorothioate oligodeoxynucleotides. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 206–221 / Antisense research and applications by JS Cohen (1993)
  30. Cook PD (1993) Medicinal chemistry strategies for antisense research. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 149–187 / Antisense research and applications by PD Cook (1993)
  31. Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens S, Markham PM, Shea JP, Crooke ST (1994a) Disposition of 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181–1190 (10.1016/S0022-3565(25)39459-0) / J Pharmacol Exp Ther by PA Cossum (1994a)
  32. Cossum PA, Truong L, Owens S, Markham PM, Shea JP, Crooke ST (1994b) Pharmacokinetics of 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J Pharmacol Exp Ther 269:89–94 (10.1016/S0022-3565(25)38714-8) / J Pharmacol Exp Ther by PA Cossum (1994b)
  33. Couture C, Chow T-Y (1992) Purification and characterization of a mammalian endoexonuclease. Nucleic Acids Res 20:4355–4361 (10.1093/nar/20.16.4355) / Nucleic Acids Res by C Couture (1992)
  34. Crooke RM (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti Cancer Drug Design 6:609–646 / Anti Cancer Drug Design by RM Crooke (1991)
  35. Crooke RM (1993a) Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester and methylphosphonate oligonucleotides. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 428–229 / Antisense research and applications by RM Crooke (1993a)
  36. Crooke RM (1993b) In vitro and in vivo toxicology of first generation analogs. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 472–492 / Antisense research and applications by RM Crooke (1993b)
  37. Crooke RM, Graham MJ, Cooke ME, Crooke ST (1995) In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462–473 (10.1016/S0022-3565(25)12072-7) / J Pharmacol Exp Ther by RM Crooke (1995)
  38. Crooke RM, Graham MJ, Martin MM, Griffey R, Cummins L (1997) Characterization of in vitro antisense oligonucleotide metabolism in rat liver homogenates. J Pharmacol Exp Ther (submitted) / Characterization of in vitro antisense oligonucleotide metabolism in rat liver homogenates. J Pharmacol Exp Ther (submitted) by RM Crooke (1997)
  39. Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmcol Toxicol 32:329–276 (10.1146/annurev.pa.32.040192.001553) / Annu Rev Pharmcol Toxicol by ST Crooke (1992)
  40. Crooke ST (1995a) Therapeutic applications of oligonucleotides. Landes, Austin Crooke ST (1995b) Oligonucleotide therapeutics. In: Wolff ME (ed) Burger’s medicinal chemistry and drug discovery, 5th edn. 1. Principles and practice. Wiley, New York / Burger’s medicinal chemistry and drug discovery by ST Crooke (1995a)
  41. Crooke ST (1996) Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev 6:145–147 (10.1089/oli.1.1996.6.145) / Antisense Nucleic Acid Drug Dev by ST Crooke (1996)
  42. Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107–129 (10.1146/annurev.pa.36.040196.000543) / Annu Rev Pharmacol Toxicol by ST Crooke (1996)
  43. Crooke ST, Lebleu B (eds) (1993) Antisense research and applications. CRC Press, Boca Raton / Antisense research and applications (1993)
  44. Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin M, Leeds JM, Barr WH (1994) A pharmacokinetic evaluation of ’4C-labeled afovirsen sodium in genital wart patients. Pharmacol Ther 56:641–646 (10.1038/clpt.1994.189) / Pharmacol Ther by ST Crooke (1994)
  45. Dean NM, McKay R (1994) Inhibition of protein kinase C-a expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762–11766 (10.1073/pnas.91.24.11762) / Proc Natl Acad Sci USA by NM Dean (1994)
  46. DiBaise JK, Ebadi M, Iversen PL (1994) Patterns of cellular uptake and effects on cell survival using antimetallothionein oligodeoxyribonucleotide conjugates in vitro. Biol Sign 3:140–149 (10.1159/000109537) / Biol Sign by JK DiBaise (1994)
  47. Eder PS, DeVine EJ, Dagle JM, Walder JA (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3’ exonuclease in plasma. Antisense Res Dev 1:141–151 (10.1089/ard.1991.1.141) / Antisense Res Dev by PS Eder (1991)
  48. Eckstein F (1985) Nucleoside phosphorothioates. Annu Rev Biochem 54:367–402 (10.1146/annurev.bi.54.070185.002055) / Annu Rev Biochem by F Eckstein (1985)
  49. Farrell CL, Bready JV, Kaufman SA, Qian Y-X, Burgess TL (1995) The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antisense Res Dev 5:175–183 (10.1089/ard.1995.5.175) / Antisense Res Dev by CL Farrell (1995)
  50. Fisher TL, Terhorst T, Cao X, Wagner RW (1993) Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides micro-injected into mammalian cells. Nucleic Acids Res 21:3857–3865 (10.1093/nar/21.16.3857) / Nucleic Acids Res by TL Fisher (1993)
  51. Gao W-Y, Jaroszewski JW, Cohen JS, Cheng Y-C (1990) Inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine. J Biol Chem 265:21072–20178 / J Biol Chem by W-Y Gao (1990)
  52. Gao W-Y, Han FS, Storm C, Egan W, Cheng Y-C (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 41:223–229 (10.1016/S0026-895X(25)08861-3) / Mol Pharmacol by W-Y Gao (1992)
  53. Gao W-Y, Storm C, Egan W, Cheng Y-C (1993) Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 43:45–50 (10.1016/S0026-895X(25)13426-3) / Mol Pharmacol by W-Y Gao (1993)
  54. Geselowitz DA, Neckers LM (1992) Analysis of oligonucleotide binding, internalization and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 2:17–25 (10.1089/ard.1992.2.17) / Antisense Res Dev by DA Geselowitz (1992)
  55. Geselowitz DA, Neckers LM (1995) Bovine serum albumin is a major oligonucleotidebinding protein found on the surface of cultured cells. Antisense Res Dev 5:213–217 (10.1089/ard.1995.5.213) / Antisense Res Dev by DA Geselowitz (1995)
  56. Giles RV, Spiller DG, Tidd DM (1993) Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anti Cancer Drug Des 8:33–51 / Anti Cancer Drug Des by RV Giles (1993)
  57. Goodarzi G, Watabe M, Watabe K (1991) Binding of oligonucleotides to cell membranes at acidic pH. Biochem Biophys Res Commun 181:1343–1351 (10.1016/0006-291X(91)92086-Y) / Biochem Biophys Res Commun by G Goodarzi (1991)
  58. Goodchild J (1990) Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconj Chem 1:165–187 (10.1021/bc00003a001) / Bioconj Chem by J Goodchild (1990)
  59. Gottikh M, Bertrand, J-R, Baud-Demattei M-V, Lescot E, Giorgi-Renault S, Shabarova Z, Malvy C (1994) αß Chimeric antisense oligonucleotides: synthesis and nuclease resistance in biological media. Antisense Res Dev 4:251–258 (10.1089/ard.1994.4.251) / Antisense Res Dev by M Gottikh (1994)
  60. Graham MJ, Freier SM, Crooke RM, Ecker DJ, Maslova RN, Lesnik EA (1993) Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 21:3737–3743 (10.1093/nar/21.16.3737) / Nucleic Acids Res by MJ Graham (1993)
  61. Graham MJ, Lemonidis KM, Monteith DM, Cooper S, Crooke ST, Crooke RM (1997) In vivo distribution and metabolism of a phosphorothioate oligonucleotide within the rat liver after intravenous administration. J Pharmacol Exp Ther (submitted) / In vivo distribution and metabolism of a phosphorothioate oligonucleotide within the rat liver after intravenous administration. J Pharmacol Exp Ther by MJ Graham (1997)
  62. Hawley P, Gibson I (1992) The detection of oligodeoxynucleotide molecules following uptake into mammalian cells. Antisense Res Dev 2:119–127 (10.1089/ard.1992.2.119) / Antisense Res Dev by P Hawley (1992)
  63. Ho PTC, Ishiguro K, Wickstrom E, Sartorelli AC (1991) Non-sequence-specific inhibition of transferrin receptor express in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev 1:329–342 (10.1089/ard.1991.1.329) / Antisense Res Dev by PTC Ho (1991)
  64. Hoke GD, Draper K, Freier SM, Gonzalez C., Driver VB, Zounes MC, Ecker DJ (1991) Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res 19:5743–5748 (10.1093/nar/19.20.5743) / Nucleic Acids Res by GD Hoke (1991)
  65. Hughes JA, Avrutskaya AV, Juliano RL (1994) Influence of base composition on membrane binding and cellular uptake of 10-mer phosphorothioate oligonucleotides in Chinese hamster ovary (CHRC5) cells. Antisense Res Dev 4:211–215 (10.1089/ard.1994.4.211) / Antisense Res Dev by JA Hughes (1994)
  66. Iversen P (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetic prologue. Anti Cancer Drug Des 6:531–538 / Anti Cancer Drug Des by P Iversen (1991)
  67. Jansen B, Wadl H, Inoue SA, Trulzsch B, Selzer E, Duchene M, Eichler H-G, Wolff K, Pehamberger H (1995) Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res Dev 5:271–277 (10.1089/ard.1995.5.271) / Antisense Res Dev by B Jansen (1995)
  68. Jaroszewski JW, Kaplan O, Syi J-L, Sehested M, Faustino PJ, Cohen JS (1990) Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun 2:287–294 (10.3727/095535490820874254) / Cancer Commun by JW Jaroszewski (1990)
  69. Kornberg A (1980) DNA replication. Freeman, San Francisco / DNA replication by A Kornberg (1980)
  70. Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA, Steinberg AD (1991) Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 1:161–171 (10.1089/ard.1991.1.161) / Antisense Res Dev by AM Krieg (1991)
  71. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR Jr (1996) Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 93:4897–4902 (10.1073/pnas.93.10.4897) / Proc Natl Acad Sci USA by JF Kukowska-Latallo (1996)
  72. Kumar S, Srinivasan H, Tewary HK, Iversen PL (1995) Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 5:131–139 (10.1089/ard.1995.5.131) / Antisense Res Dev by S Kumar (1995)
  73. Leeds JM, Geary RS (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides in humans. In: Crooke ST (ed) Antisense research and application. Springer, Berlin Heidelberg New York / Antisense research and application by JM Leeds (1997)
  74. Leeds JM, Truong LA, Cossum P, Prowse C, Crooke ST, Kornbrust D (1994) Interaction of phosphorothioate oligonucleotides with plasma proteins. Pharmacol Res 11:S-352 / Pharmacol Res by JM Leeds (1994)
  75. Leeds JM, Graham MJ, Truong L, Cummins LL (1996) Quantitation of phos-phorothioate oligonucleotides in human plasma. Anal Biochem 235:36–43 (10.1006/abio.1996.0088) / Anal Biochem by JM Leeds (1996)
  76. Leonetti J-P, Mechti, Degols C, Gagnor C, Lebleu B (1991) Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88:2702–2706 (10.1073/pnas.88.7.2702) / Proc Natl Acad Sci USA by J-P Leonetti (1991)
  77. LeRoy C, Leduque P, Dubois PM, Saez JM, Langlois D (1996) Repression of transforming growth factor ßl protein by antisense oligonucleotide induced increase of adrenal cell differentiated functions. J Biol Chem 271:11027–11033 (10.1074/jbc.271.18.11027) / J Biol Chem by C LeRoy (1996)
  78. Levis JT, Butler WO, Tseng BY, Ts’o POP (1995) Cellular uptake of olig-odeoxyribonucleoside methylphosphonates. Antisense Res Dev 5:251–259 (10.1089/ard.1995.5.251) / Antisense Res Dev by JT Levis (1995)
  79. Lewis JG, Lin K-Y, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA Jr, Hendren RW, Wagner RW (1996) A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmic DNA. Proc Natl Acad Sci USA 93:3176–3181 (10.1073/pnas.93.8.3176) / Proc Natl Acad Sci USA by JG Lewis (1996)
  80. Liang W, Shi Z, Deshpande D, Malanga CJ, Rojanasakul Y (1996) Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochem Biophys Acta 1279:227–234 (10.1016/0005-2736(95)00237-5) / Biochem Biophys Acta by W Liang (1996)
  81. Lloyd RS, Linn S (1993) Nucleases involved in DNA repair. In: Linn SM, Lloyd RS, Roberts RJ (eds) Nucleases, 2nd edn, monograph 25. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 263–316 / Nucleases, 2nd edn, monograph by RS Lloyd (1993)
  82. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe S, Cohen JS, Neckers LM (1989) Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474–3478 (10.1073/pnas.86.10.3474) / Proc Natl Acad Sci USA by SL Loke (1989)
  83. Marcus-Sekura CJ, Woerner AM, Shinozuka K, Zon G, Quinnan GV, Jr (1987) Comparative inhibition of chloramphenical acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res 15:5749–5963 (10.1093/nar/15.14.5749) / Nucleic Acids Res by CJ Marcus-Sekura (1987)
  84. Marti G, Egan W, Noguchi P, Zon G, Matsukura M, Broder S (1992) Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev 2:27–39 (10.1089/ard.1992.2.27) / Antisense Res Dev by G Marti (1992)
  85. Miller PS, McParland KB, Jayaraman K, Ts’o POP (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20:1874–1880 (10.1021/bi00510a024) / Biochemistry by PS Miller (1981)
  86. Miller PS, Ts’o POP, Hogrefe RI, Reynolds MA, Arnold LA Jr (1993) Anticode oligonucleoside methylphosphonates and their psoralen derivatives. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 190–203 / Antisense research and applications by PS Miller (1993)
  87. Nakai D, Sewita T, Iwasa T, Aiwasa S, Shoji Y, Mizushima Y, Sugiyama Y (1996) Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J Pharmacol Exp Ther 278:1362–1372 (10.1016/S0022-3565(25)20791-1) / J Pharmacol Exp Ther by D Nakai (1996)
  88. Neckers LM (1993) Cellular internalization of oligodeoxynucleotides. In: Crooke ST, Lebleu B (eds) Antisense research and applications. CRC Press, Boca Raton, pp 452–460 / Antisense research and applications by LM Neckers (1993)
  89. Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103:569–575 (10.1111/1523-1747.ep12396876) / J Invest Dermatol by FO Nestle (1994)
  90. Noonberg SB, Garovoy MR, Hunt CA (1993) Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol 101:727–731 (10.1111/1523-1747.ep12371683) / J Invest Dermatol by SB Noonberg (1993)
  91. Olsen DB, Kotzorek G, Eckstein F (1990) Investigation of the inhibitory role of phosphorothioate internucleotide linkages on the catalytic activity of the restriction endonuclease EcoRV. Biochemistry 29:9546–9551 (10.1021/bi00493a008) / Biochemistry by DB Olsen (1990)
  92. Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton JS (1996) A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev 6:169–175 (10.1089/oli.1.1996.6.169) / Antisense Nucleic Acid Drug Dev by M Partridge (1996)
  93. Pickering JG, Isner JM, Ford CM, Weir L, Lazarovits A, Rocnik EF, Chow LH (1996) Processing of chimeric antisense antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restonosis after angioplasty. Circulation 93:772–780 (10.1161/01.CIR.93.4.772) / Circulation by JG Pickering (1996)
  94. Robinson LA, Smith, LJ, Fontaine MP, Kay HD, Mountjoy CP, Pirruccello SJ (1995) c-myc antisense oligodeoxynucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg 60:1583–1591 (10.1016/0003-4975(95)00759-8) / Ann Thorac Surg by LA Robinson (1995)
  95. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thoung NT, Helene C (1991) Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cell proliferation. EMBO J 10:1111–1118 (10.1002/j.1460-2075.1991.tb08051.x) / EMBO J by T Saison-Behmoaras (1991)
  96. Sands, H, Feret G, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994) Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932–943 (10.1016/S0026-895X(25)10208-3) / Mol Pharmacol by H Sands (1994)
  97. Sasmor HM, Dellinger DJ, Zenk P, Lee LP (1995) A practical method for the synthesis and purification of ’4C-labeled oligonucleotides. J Lab Cpds Rad Pharm 36:15–31 (10.1002/jlcr.2580360103) / J Lab Cpds Rad Pharm by HM Sasmor (1995)
  98. Shaw J-P, Kent K, Bird J, Fishback, J, Froehler B (1991) Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res 19:747–750 (10.1093/nar/19.4.747) / Nucleic Acids Res by J-P Shaw (1991)
  99. Shoji Y, Akhtar A, Periasamy A, Herman B, Juliano RL (1991) Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19:5543–5550 (10.1093/nar/19.20.5543) / Nucleic Acids Res by Y Shoji (1991)
  100. Smetsers TFCM, Skorski T, van de Locht LTF, Wessels HMC, Pennings AHM, deWitte T, Calabretta B, Mensink EJBM (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8:129–140 / Leukemia by TFCM Smetsers (1994)
  101. Spiller DG, Tidd DM (1992) The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anti Cancer Drug Des 7:115–129 / Anti Cancer Drug Des by DG Spiller (1992)
  102. Spiller DG, Tidd DM (1995) Nuclear delivery of antisense oligodeoxynucleotides though reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev 5:13–21 (10.1089/ard.1995.5.13) / Antisense Res Dev by DG Spiller (1995)
  103. Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004–1012 (10.1126/science.8351515) / Science by CA Stein (1993)
  104. Stein CA, Subasinghe C, Shinozuka K, Cohen JS (1988a) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16:3206–3221 (10.1093/nar/16.8.3209) / Nucleic Acids Res by CA Stein (1988a)
  105. Stein CA, Mori K, Loke SL, Subasinghe C, Shinozuka K, Cohen JS, Neckers LM (1988b) Phosphorothioate and normal oligonucleotides with 5’-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene 72:333–341 (10.1016/0378-1119(88)90160-6) / Gene by CA Stein (1988b)
  106. Stein CA, Iversen PL, Subasinghe C, Cohen JS, Stec WJ, Zon G (1990) Preparation of 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Anal Biochem 188:11–16 (10.1016/0003-2697(90)90607-B) / Anal Biochem by CA Stein (1990)
  107. Stein CA, Neckers LM, Nair BC, Mumbauer S, Hoke G, Pal R (1991) Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp20 to CD4. J Acquir Immune Defic Syndr 4:686–693 / J Acquir Immune Defic Syndr by CA Stein (1991)
  108. Stein CA, Cleary AM, Yakubov L, Lederman S (1993a) Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res Dev 3:19–31 (10.1089/ard.1993.3.19) / Antisense Res Dev by CA Stein (1993a)
  109. Stein CA, Tonkinson JL, Zhang L-M, Yakubov L, Gervasoni J, Taub R, Rotenberg SA (1993b) Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855–4861 (10.1021/bi00069a022) / Biochemistry by CA Stein (1993b)
  110. Stepkowski SM, Tu Y, Condon TP, Bennett CF (1994) Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 153:5336–5346 (10.4049/jimmunol.153.11.5336) / J Immunol by SM Stepkowski (1994)
  111. Tabor CW, Tabor H (1984) Polyamines. Annu Rev Biochem 53:749–790 (10.1146/annurev.bi.53.070184.003533) / Polyamines. Annu Rev Biochem by CW Tabor (1984)
  112. Temsamani J, Kubert M, Tang J, Padmapriya A, Agrawal S (1994) Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev 4:35–42 (10.1089/ard.1994.4.35) / Antisense Res Dev by J Temsamani (1994)
  113. Thierry AR, Dritschilo A (1992) Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20:5691–5698 (10.1093/nar/20.21.5691) / Nucleic Acids Res by AR Thierry (1992)
  114. Tidd DM (1990) A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res 10:1169–1182 / Anticancer Res by DM Tidd (1990)
  115. Tidd DM, Warenius HM (1989) Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups. Br J Cancer 60:343–350 (10.1038/bjc.1989.283) / Br J Cancer by DM Tidd (1989)
  116. Tolou H (1993) Administration of oligonucleotides to cultured cells by calcium phosphate precipitation method. Anal Biochem 215:156–158 (10.1006/abio.1993.1568) / Anal Biochem by H Tolou (1993)
  117. Tonkinson JL, Stein CA (1994) Patterns of intracellular compartmentalization, trafficking and acidification of 5’ fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res 22:4268–4275 (10.1093/nar/22.20.4268) / Nucleic Acids Res by JL Tonkinson (1994)
  118. Vasanthakumar G, Ahmed NA (1989) Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun 1:225–232 / Cancer Commun by G Vasanthakumar (1989)
  119. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333–335 (10.1038/372333a0) / Nature by RW Wagner (1994)
  120. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS (1995) Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to the folate via polyethylene glycol. Proc Natl Acad Sci USA 92:3318–3322 (10.1073/pnas.92.8.3318) / Proc Natl Acad Sci USA by S Wang (1995)
  121. Wickstrom E (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13:97–102 (10.1016/0165-022X(86)90021-7) / J Biochem Biophys Methods by E Wickstrom (1986)
  122. Woolf TM, Jennings CGB, Rebagliati M, Melton DA (1990) The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Acids Res 18:1763–1769 (10.1093/nar/18.7.1763) / Nucleic Acids Res by TM Woolf (1990)
  123. Wu-Pong S, Weiss TL, Hunt CA (1992) Antisense c-myc oligodeoxyribonucleotide cellular uptake. Pharmacol Res 9:1010–1017 (10.1023/A:1015846209681) / Pharmacol Res by S Wu-Pong (1992)
  124. Wu-Pong S, Weiss TL, Hunt AC (1994) Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev 4:155–163 (10.1089/ard.1994.4.155) / Antisense Res Dev by S Wu-Pong (1994)
  125. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV (1989) Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454–6458 (10.1073/pnas.86.17.6454) / Proc Natl Acad Sci USA by LA Yakubov (1989)
  126. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280–288 (10.1073/pnas.75.1.280) / Proc Natl Acad Sci USA by PC Zamecnik (1978)
  127. Zamecnik P, Aghajanian J, Zamecnik M, Goodchild J, Witman G (1994) Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc Natl Acad Sci USA 91:3156–3160 (10.1073/pnas.91.8.3156) / Proc Natl Acad Sci USA by P Zamecnik (1994)
  128. Zerial A, Thuong NT, Helene C (1987) Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res 15:9909–9919 (10.1093/nar/15.23.9909) / Nucleic Acids Res by A Zerial (1987)
  129. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53–66 (10.1089/ard.1993.3.53) / Antisense Res Dev by Q Zhao (1993)
  130. Zhao Q, Waldeschmidt T, Fisher R, Herrera CJ, Krieg AM (1994) Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 84:3660–3666 (10.1182/blood.V84.11.3660.bloodjournal84113660) / Blood by Q Zhao (1994)
  131. Zhao Q, Temsamani J, Agrawal S (1995) Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res Dev 5:185–192 (10.1089/ard.1995.5.185) / Antisense Res Dev by Q Zhao (1995)
  132. Zhao Q, Song X, Waldschmidt T, Fisher E, Krief AM (1996) Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 88:1788–1795 (10.1182/blood.V88.5.1788.1788) / Blood by Q Zhao (1996)
  133. Zon G (1989) Oligonucleotide analogues as potential chemotherapeutic agents. Pharmacol Res 5:539–549 (10.1023/A:1015985728434) / Pharmacol Res by G Zon (1989)
Dates
Type When
Created 14 years, 2 months ago (June 26, 2011, 12:02 p.m.)
Deposited 5 months, 3 weeks ago (March 6, 2025, 1:31 p.m.)
Indexed 5 months, 3 weeks ago (March 7, 2025, 12:21 a.m.)
Issued 27 years, 7 months ago (Jan. 1, 1998)
Published 27 years, 7 months ago (Jan. 1, 1998)
Published Print 27 years, 7 months ago (Jan. 1, 1998)
Funders 0

None

@inbook{Crooke_1998, title={In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides}, ISBN={9783642587856}, ISSN={1865-0325}, url={http://dx.doi.org/10.1007/978-3-642-58785-6_3}, DOI={10.1007/978-3-642-58785-6_3}, booktitle={Antisense Research and Application}, publisher={Springer Berlin Heidelberg}, author={Crooke, R. M.}, year={1998}, pages={103–140} }